Market revenue in 2023 | USD 88.7 million |
Market revenue in 2030 | USD 183.2 million |
Growth rate | 10.9% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase III |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Takeda Pharmaceutical Co Ltd, Roche Holding AG ADR, Pfizer Inc, AstraZeneca PLC, Novartis AG ADR, Labcorp Holdings Inc, IQVIA Holdings Inc, Charles River Laboratories International Inc, Icon PLC, PAREXEL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 42.73% in 2023. Horizon Databook has segmented the Thailand rare disease clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand rare disease clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Thailand rare disease clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account